MacroGenics, Inc. (MGNX)
3.74
+0.19
(+5.35%)
USD |
NASDAQ |
Oct 09, 16:00
3.74
0.00 (0.00%)
After-Hours: 20:00
MacroGenics Enterprise Value : 262.98M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 262.98M |
| October 08, 2026 | 250.88M |
| October 07, 2026 | 250.88M |
| October 06, 2026 | 256.61M |
| October 05, 2026 | 264.89M |
| October 02, 2026 | 252.79M |
| October 01, 2026 | 254.07M |
| September 30, 2026 | 270.61M |
| September 29, 2026 | 264.89M |
| September 28, 2026 | 283.34M |
| September 25, 2026 | 262.98M |
| September 24, 2026 | 266.80M |
| September 23, 2026 | 266.80M |
| September 22, 2026 | 287.16M |
| September 21, 2026 | 287.16M |
| September 18, 2026 | 288.44M |
| September 17, 2026 | 287.80M |
| September 16, 2026 | 284.62M |
| September 15, 2026 | 282.07M |
| September 14, 2026 | 292.25M |
| September 11, 2026 | 279.52M |
| September 10, 2026 | 277.62M |
| September 09, 2026 | 286.53M |
| September 08, 2026 | 299.89M |
| September 04, 2026 | 304.98M |
| Date | Value |
|---|---|
| September 03, 2026 | 295.44M |
| September 02, 2026 | 299.89M |
| September 01, 2026 | 282.07M |
| August 31, 2026 | 278.89M |
| August 28, 2026 | 287.80M |
| August 27, 2026 | 284.62M |
| August 26, 2026 | 282.07M |
| August 25, 2026 | 290.34M |
| August 24, 2026 | 280.80M |
| August 21, 2026 | 285.89M |
| August 20, 2026 | 283.98M |
| August 19, 2026 | 290.34M |
| August 18, 2026 | 285.25M |
| August 17, 2026 | 283.34M |
| August 14, 2026 | 293.53M |
| August 13, 2026 | 284.62M |
| August 12, 2026 | 280.80M |
| August 11, 2026 | 274.43M |
| August 10, 2026 | 284.62M |
| August 07, 2026 | 282.07M |
| August 06, 2026 | 280.16M |
| August 05, 2026 | 273.16M |
| August 04, 2026 | 273.16M |
| August 03, 2026 | 268.07M |
| July 31, 2026 | 259.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 208.88B |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.64M |
| Revenue (Quarterly) | 32.83M |
| Total Expenses (Quarterly) | 102.47M |
| EPS Diluted (Quarterly) | 0.3069 |
| Gross Profit Margin (Quarterly) | 97.84% |
| Profit Margin (Quarterly) | -212.1% |
| Earnings Yield | -6.16% |
| Normalized Earnings Yield | -6.160 |